Literature DB >> 22958287

Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin.

Mette Møller Handrup1, Kurt Fuursted, Peter Funch, Jens Kjølseth Møller, Henrik Schrøder.   

Abstract

Taurolidine has demonstrated inhibition of biofilm formation in vitro. The aim of this study was to compare the effect of catheter locking with taurolidine vs heparin in biofilm formation in central venous catheters. Forty-eight children with cancer were randomized to catheter locking by heparin (n = 22) or taurolidine (n = 26), respectively. After removal, catheters were examined by standardized scanning electron microscopy to assess quantitative biofilm formation. Biofilm was present if morphologically typical structures and bacterial cells were identified. Quantitative and semi-quantitative cultures were also performed. Biofilm was identified in 23 of 26 catheters from the taurolidine group and 21 of 22 catheters from the heparin group. A positive culture was made of six of the catheters locked with taurolidine and heparin, respectively (p = 0.78). The rate of catheter-related bloodstream infections (CRBSI) was 0.1 per 1000 catheter-days using taurolidine and 0.9 per 1000 catheter-days using heparin (p = 0.03). This randomized trial confirmed that the use of taurolidine as catheter-lock compared with heparin reduced the rate of CRBSIs; this reduction was not related to a reduction in the intraluminal biofilm formation and the rate of bacterial colonization detected by scanning electron microscopy in the two groups.
© 2012 The Authors APMIS © 2012 APMIS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22958287     DOI: 10.1111/j.1600-0463.2012.02910.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  16 in total

1.  Ambulatory pediatric oncology CLABSIs: epidemiology and risk factors.

Authors:  Michael L Rinke; Aaron M Milstone; Allen R Chen; Kara Mirski; David G Bundy; Elizabeth Colantuoni; Miriana Pehar; Cynthia Herpst; Marlene R Miller
Journal:  Pediatr Blood Cancer       Date:  2013-07-23       Impact factor: 3.167

2.  Bloodstream infection in paediatric cancer centres--leukaemia and relapsed malignancies are independent risk factors.

Authors:  R A Ammann; H J Laws; D Schrey; K Ehlert; O Moser; D Dilloo; U Bode; A Wawer; A Schrauder; G Cario; A Laengler; N Graf; R Furtwängler; A Simon
Journal:  Eur J Pediatr       Date:  2015-03-26       Impact factor: 3.183

3.  Short bowel syndrome in infancy: recent advances and practical management.

Authors:  Elena Cernat; Chloe Corlett; Natalia Iglesias; Nkem Onyeador; Julie Steele; Akshay Batra
Journal:  Frontline Gastroenterol       Date:  2020-12-16

4.  The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions.

Authors:  Yannick Wouters; Gina R H Mennen; René H M Te Morsche; Hennie M J Roelofs; Geert J A Wanten
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

Review 5.  Prophylactic antibiotics for preventing gram-positive infections associated with long-term central venous catheters in adults and children receiving treatment for cancer.

Authors:  Ceder van den Bosch; Job van Woensel; Marianne D van de Wetering
Journal:  Cochrane Database Syst Rev       Date:  2021-10-07

6.  In vitro activity of taurolidine gel on bacteria associated with periodontitis.

Authors:  Sigrun Eick; Nicoletta Gloor; Cecilia Püls; Jürg Zumbrunn; Anton Sculean
Journal:  Clin Oral Investig       Date:  2015-08-09       Impact factor: 3.573

7.  In Vitro Assessment of the Antimicrobial Efficacy of Optimized Nitroglycerin-Citrate-Ethanol as a Nonantibiotic, Antimicrobial Catheter Lock Solution for Prevention of Central Line-Associated Bloodstream Infections.

Authors:  Ruth A Reitzel; Joel Rosenblatt; Cheryl Hirsh-Ginsberg; Kimberly Murray; Anne-Marie Chaftari; Ray Hachem; Issam Raad
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

8.  Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients.

Authors:  Néstor Fontseré; Celia Cardozo; Javier Donate; Alex Soriano; Mercedes Muros; Mercedes Pons; Josep Mensa; Josep M Campistol; Juan F Navarro-González; Francisco Maduell
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

Review 9.  Anticoagulation for people with cancer and central venous catheters.

Authors:  Lara A Kahale; Ibrahim G Tsolakian; Maram B Hakoum; Charbel F Matar; Maddalena Barba; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2018-06-01

Review 10.  Taurolidine lock solutions for the prevention of catheter-related bloodstream infections: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yong Liu; An-Qiang Zhang; Lin Cao; Hong-Tao Xia; Jun-Jie Ma
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.